AIMS/HYPOTHESIS: Only a few longitudinal molecular studies of enterovirus and islet autoimmunity have been reported, and positive results seem to be limited to Finland. We aimed to investigate an association between enterovirus RNA in blood and islet autoimmunity in the MIDIA study from Norway, a country which largely shares environmental and economic features with Finland. METHODS: We analysed serial blood samples collected at ages 3, 6, and 9 months and then annually from 45 children who developed confirmed positivity for at least two autoantibodies (against insulin, GAD65 and IA-2) and 92 matched controls, all from a cohort of children with a single high-risk HLA-DQ-DR genotype. Enterovirus was tested in RNA extracted from frozen blood cell pellets, using real-time RT-PCR with stringent performance control. RESULTS: Out of 807 blood samples, 72 (8.9%) were positive for enterovirus. There was no association between enterovirus RNA and islet autoimmunity in samples obtained strictly before (7.6% cases, 10.0% controls, OR 0.75 [95% CI 0.36, 1.57]), or strictly after the first detection of islet autoantibodies (10.5% case, 5.8% controls, OR 2.00 [95% CI 0.64, 6.27]). However, there was a tendency towards a higher frequency of enterovirus detection in the first islet autoantibody-positive sample (15.8%) compared with the corresponding time point in matched controls (3.2%, OR 8.7 [95% CI 0.97, 77]). Neither of these results was changed by adjusting for potential confounders, restricting to various time intervals or employing various definitions of enterovirus positivity. CONCLUSIONS/ INTERPRETATION: Positivity for enterovirus RNA in blood did not predict the later induction of islet autoantibodies, but enterovirus tended to be detected more often at the islet autoantibody seroconversion stage.
AIMS/HYPOTHESIS: Only a few longitudinal molecular studies of enterovirus and islet autoimmunity have been reported, and positive results seem to be limited to Finland. We aimed to investigate an association between enterovirus RNA in blood and islet autoimmunity in the MIDIA study from Norway, a country which largely shares environmental and economic features with Finland. METHODS: We analysed serial blood samples collected at ages 3, 6, and 9 months and then annually from 45 children who developed confirmed positivity for at least two autoantibodies (against insulin, GAD65 and IA-2) and 92 matched controls, all from a cohort of children with a single high-risk HLA-DQ-DR genotype. Enterovirus was tested in RNA extracted from frozen blood cell pellets, using real-time RT-PCR with stringent performance control. RESULTS: Out of 807 blood samples, 72 (8.9%) were positive for enterovirus. There was no association between enterovirus RNA and islet autoimmunity in samples obtained strictly before (7.6% cases, 10.0% controls, OR 0.75 [95% CI 0.36, 1.57]), or strictly after the first detection of islet autoantibodies (10.5% case, 5.8% controls, OR 2.00 [95% CI 0.64, 6.27]). However, there was a tendency towards a higher frequency of enterovirus detection in the first islet autoantibody-positive sample (15.8%) compared with the corresponding time point in matched controls (3.2%, OR 8.7 [95% CI 0.97, 77]). Neither of these results was changed by adjusting for potential confounders, restricting to various time intervals or employing various definitions of enterovirus positivity. CONCLUSIONS/ INTERPRETATION: Positivity for enterovirus RNA in blood did not predict the later induction of islet autoantibodies, but enterovirus tended to be detected more often at the islet autoantibody seroconversion stage.
Authors: Kimmo Salminen; Karita Sadeharju; Maria Lönnrot; Paula Vähäsalo; Antti Kupila; Sari Korhonen; Jorma Ilonen; Olli Simell; Mikael Knip; Heikki Hyöty Journal: J Med Virol Date: 2003-01 Impact factor: 2.327
Authors: Barbara M Schulte; Judith Bakkers; Kjerstin H W Lanke; Willem J G Melchers; Ciska Westerlaken; Wil Allebes; Henk-Jan Aanstoot; G Jan Bruining; Gosse J Adema; Frank J M Van Kuppeveld; Jochem M D Galama Journal: Viral Immunol Date: 2010-02 Impact factor: 2.257
Authors: E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Hanna Viskari; Johnny Ludvigsson; Raivo Uibo; Lina Salur; Dalia Marciulionyte; Robert Hermann; Gyula Soltesz; Martin Füchtenbusch; Anette-G Ziegler; Anita Kondrashova; Anatolij Romanov; Mikael Knip; Heikki Hyöty Journal: J Med Virol Date: 2004-04 Impact factor: 2.327
Authors: Sami Oikarinen; Mika Martiskainen; Sisko Tauriainen; Heini Huhtala; Jorma Ilonen; Riitta Veijola; Olli Simell; Mikael Knip; Heikki Hyöty Journal: Diabetes Date: 2010-10-13 Impact factor: 9.461
Authors: Hanna Honkanen; Sami Oikarinen; Noora Nurminen; Olli H Laitinen; Heini Huhtala; Jussi Lehtonen; Tanja Ruokoranta; Minna M Hankaniemi; Valérie Lecouturier; Jeffrey W Almond; Sisko Tauriainen; Olli Simell; Jorma Ilonen; Riitta Veijola; Hanna Viskari; Mikael Knip; Heikki Hyöty Journal: Diabetologia Date: 2017-01-09 Impact factor: 10.122
Authors: Alexandra Coomans de Brachène; Angela Castela; Anyïshai E Musuaya; Lorella Marselli; Piero Marchetti; Decio L Eizirik Journal: Auto Immun Highlights Date: 2021-03-27
Authors: Julius O Nyalwidhe; Agata Jurczyk; Basanthi Satish; Sambra Redick; Natasha Qaisar; Melanie I Trombly; Pranitha Vangala; Riccardo Racicot; Rita Bortell; David M Harlan; Dale L Greiner; Michael A Brehm; Jerry L Nadler; Jennifer P Wang Journal: Microorganisms Date: 2020-02-20
Authors: Clare L Faulkner; Yi Xuan Luo; Sonia Isaacs; William D Rawlinson; Maria E Craig; Ki Wook Kim Journal: Rev Med Virol Date: 2020-12-30 Impact factor: 6.989